Real-World Data in EU Early Access Programmes: GSK Case Study
- Defining the minimal dataset that aligns with both regulatory and payor requirements while maintaining feasibility in early access settings
- Addressing variability in RWD collection across EU countries and navigating differing expectations from regulators and health technology assessment (HTA) bodies
- Overcoming data collection limitations in different EAP models, from named-patient programs to broader early access frameworks